Introduction {#Sec1}
============

Choline-PET/CT is widely used in patients with prostate cancer. Clinically, the imaging technique is used mainly for restaging of patients with a biochemical relapse and less frequently for initial staging. One of the strengths of choline-PET/CT is the detection and localisation of prostate cancer metastases in patients with slightly elevated PSA. Lymph node metastases can be detected in lymph nodes, which do not show malignant characteristics on conventional imaging such as CT and MRI. Patients with limited lymph node metastases may be selected for procedures with curative intent, while patients with more extensive disease can be protected from the morbidity of senseless aggressive therapies.

Detection of lymph node metastases may be hampered by high physiological choline uptake in the gastrointestinal tract commonly seen on choline-PET/CT. In the literature, fasting is frequently proposed before ^18^F-fluorocholine PET/CT, as can be found in a summary of literature by Chondrogiannis et al. \[[@CR1]\]. Four hours of fasting before administration of ^11^C-choline is suggested in a document of the Society of Nuclear Medicine and Molecular Imaging \[[@CR2]\]; however, both the Society of Nuclear Medicine and Molecular Imaging and the European Association of Nuclear Medicine have no specific guidelines for ^18^F- or ^11^C-choline PET/CT. To the best of our knowledge, there is no evidence that supports fasting prior to choline-PET/CT in order to suppress physiological choline uptake in the gastrointestinal tract. In a small animal study, fasting was not found to affect tracer uptake in the liver for both ^11^C-choline and ^18^F-fluorocholine \[[@CR3]\]. This study aims to determine the impact of fasting, for at least 6 h, on ^18^F-fluorocholine uptake in the gastrointestinal tract.

Methods {#Sec3}
=======

From May 2013 data of all ^18^F-fluorocholine-PET/CTs at our department were prospectively entered in a database. All patients gave written consent for the use of their anonymous data. Initially, all patients were scanned without prior fasting. Due to the observed high physiological ^18^F-fluorocholine uptake in the intestine, the patient preparation protocol for prostate cancer patients was changed after the first 40 patients had been scanned. In the revised patient preparation protocol, patients were asked to fast for at least 6 h prior to administration of ^18^F-fluorocholine. All scans were evaluated after a second cohort of 40 patients was scanned that had properly followed the revised patient preparation protocol.

LIST-mode data of the prostatic region were acquired for 10 min directly after ^18^F-fluorocholine administration (190 MBq, mean), followed by late images from the inguinal region to the base of the skull approximately 45 min later (Siemens Biograph-16 TruePoint PET/CT, Siemens Healthcare, Knoxville, USA).

For each patient, the LIST-mode data was used to determine the choline time-activity pattern in the intestine during the first 10 min after ^18^F-fluorocholine administration (software: Siemens syngo.via, Siemens Healthcare, Knoxville, USA). The Kolmogorov-Smirnov test was used to check for a normal distribution in the data. A *T* test or the Mann-Whitney *U* test was used to check for the differences between the groups at each time point after injection. A *T* test was used when the data in both groups showed a normal distribution; otherwise, the Mann-Witney *U* test was used.

Late data was used to determine the ^18^F-fluorocholine uptake in the liver, spleen, stomach, pancreas and intestine. In five different regions: 1 cm or less in the proximity of the aorta, both the left and right common iliac arteries, and both the left and right external iliac arteries, intestinal activity were measured. A *T* test or the Mann-Whitney *U* test was used to check for the differences between the groups in measured SUV~max~ and SUV~peak~, for each evaluated organ/region.

Findings {#Sec4}
========

Patient population {#Sec5}
------------------

In both the fasting and non-fasting group, 40 patients were included. Mean age was 71.9 years (range 59--83) and 69.1 (range 51--83) for the fasting and non-fasting group, respectively. Median PSA was 5.6 (0.3--194) and 4.3 (1.0--43.6), respectively. Indication for ^18^F-fluorocholine PET/CT was primary staging in six patients and three patients, biochemical relapse in 33 and 37 patients and other in one patient and zero patients for the fasting and non-fasting group, respectively.

Early dynamic phase {#Sec6}
-------------------

^18^F-fluorocholine PET/CT shows a rapid uptake of the ^18^F-fluorocholine in the intestine in the first 2 min followed by a more or less stable concentration. No statistical differences were found between the fasting and non-fasting groups at any time-point (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Mean intensity and uptake pattern of ^18^F-fluorocholine in intestine in the pelvis in the first 10 min after intravenous ^18^F-fluorocholine administration in both the fasting and non-fasting group. Error bars showing the standard deviation

Late phase {#Sec7}
----------

In all patients' intestinal activity, which possibly interfered with lymph node metastases detection, was found near the aorta, especially in the duodenum. Possible interfering activity was found near the right common iliac artery in 65 and 80 % of the patients for the non-fasting and fasting group, respectively, right external iliac artery (93 and 98 %) and left external iliac artery (68 and 80 %). Activity near the left common iliac artery was found less frequently (37 and 45 %). The intensity of ^18^F-fluorocholine uptake in these regions was not significantly different between the fasting and non-fasting groups (Table [1](#Tab1){ref-type="table"}, Fig. [2](#Fig2){ref-type="fig"}). In general, the intestinal activity near the aorta is higher than in the other regions, 0.003 ≥ *p* ≥ 0.000 for SUV~max~ and 0.002 ≥ *p* ≥ 0.000 for SUV~mean~ (ANOVA with post hoc Scheffe's test). No significant differences were found between the activities in the other regions.Table 1Intensity of ^18^F-fluorocholine uptake in the intestine in five perivascular regions in pelvis and abdomen for fasting and non-fasting groupFastingNumberMean*σp*SUV~max~ intestine in region nearAbdominal aortaNo405.691.430.421\*Yes405.251.69Right common iliac arteryNo263.271.790.876^\#^Yes323.251.56Left common iliac arteryNo154.662.480.075\*Yes183.641.59Right external iliac arteryNo373.651.500.954^\#^Yes393.581.21Left external iliac arteryNo273.882.050.909^\#^Yes323.501.41SUV~peak~ intestine in region nearAbdominal aortaNo404.911.240.226\*Yes404.441.37Right common iliac arteryNo262.781.550.784^\#^Yes322.771.33Left common iliac arteryNo153.982.030.115\*Yes183.111.39Right external iliac arteryNo372.931.080.909^\#^Yes392.991.05Left external iliac arteryNo273.141.630.982^\#^Yes322.881.05Statistical analysis with \**T* test and ^\#^Mann-Whitney *U* testFig. 2Example of ^18^F-fluorocholine PET/CT of a patient from the non-fasting group (**a**) and a patient from the fasting group (**b**). The fused images show transaxial views at the level of the abdominal aorta and the common iliac arteries

No significant differences were found in the ^18^F-fluorocholine activity uptake in the liver, spleen, stomach and pancreas between the fasting and the non-fasting groups (Table [2](#Tab2){ref-type="table"}).Table 2Intensity of ^18^F-fluorocholine uptake in pancreas, liver, spleen and stomach for fasting and non-fasting groupFastingNumberMean*σp*SUV~max~PancreasNo409.392.100.661\*Yes409.142.83LiverNo4011.042.340.165\*Yes4011.782.39SpleenNo404.720.650.326\*Yes404.911.01StomachNo407.151.790.952\*Yes407.121.78SUV~peak~PancreasNo408.411.810.526\*Yes408.102.51LiverNo4010.212.270.128^\#^Yes4010.872.19SpleenNo404.250.540.620^\#^Yes404.450.95StomachNo406.341.740.860\*Yes406.271.62Statistical analysis with \**T* test and ^\#^Mann-Whitney *U* test

Discussion {#Sec8}
==========

The data of our study shows that physiological intestine activity in the vicinity of the abdominal aorta and iliac arteries, regions in which lymph node metastases of prostate cancer are frequently found, is present in all prostate cancer patients receiving ^18^F-fluorocholine PET/CT, especially near the abdominal aorta. In earlier data from our group, we found in 100 patients that the activity (SUV~max~) in malignant lymph nodes and physiological intestine activity does not significantly differ at both early and late data acquisition time points (Fig. [3](#Fig3){ref-type="fig"}, unpublished). Therefore, interference of physiological activity in the intestine with detection of lymph node metastases is realistic.Fig. 3Boxplots of intensity (SUV~max~) of ^18^F-fluorocholine uptake in malignant lymph nodes and intestine in the early and late phase. No statistically significant difference was found. Early phase *p* = 0.823 and late phase *p* = 0.897 (Mann-Whitney *U* test). Boxplots showing the median, first and third quartile, maximum and minimal values not considered an outlier and outliers (\>1.5 interquartile range)

Most papers on acquisition protocols of ^18^F-fluorocholine deal with the time-point of acquisition and with the effects of voiding and hydration on detection of lesions in the prostate. Fasting is regularly proposed in acquisition protocols without scientific support \[[@CR1]\]. Our data show that the nutritional status has no impact on the uptake of ^18^F-fluorocholine in the gastrointestinal tract and, more specifically, in regions in the gastrointestinal tract that may interfere with the detection of lymph node metastases.

The CT part of the PET/CT is important to detect lymph nodes in areas with high intestinal activity. To distinguish lymph nodes in these areas, acquisition of CT images of diagnostic quality with administration of intravenous iodinated contrast is necessary. Once lymph nodes are detected on CT, the combination of PET and CT may distinguish malignant lymph nodes from physiological lymph nodes, however, especially in small lymph nodes, characterisation may remain difficult.

The statistical power may be a shortcoming of the study. In all regions, the observed differences in the mean SUV~max~ and SUV~peak~ are relatively small in comparison to the observed standard deviation. One could suggest that the large study populations would be needed to exclude the presence of statistically significant differences. However, in our opinion, the clinical value of such findings would still be irrelevant. Regarding the overlap of found ^18^F-fluorocholine intensity in all intestine regions in both groups with the intensity in malignant lymph nodes, no effects on the detection of lymph node metastases are expected.

Conclusion {#Sec9}
==========

Intestinal activity that possibly interferes with the detection of lymph node metastases is encountered in all prostate cancer patients receiving ^18^F-fluorocholine PET/CT. Fasting for at least 6 h before administration of ^18^F-fluorocholine does not influence the uptake of ^18^F-fluorocholine in the gastrointestinal tract in these patients. Therefore, fasting is not recommended in our opinion.
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